Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05962710 · ClinicalTrials.gov registry record

FreeStyle Libre 3 Continuous Glucose Monitoring System

A clinical trial, sponsored by Abbott Diabetes Care.

Terminated
Registry status
7
Enrollment target

NCT05962710: Clinical Trial study, sponsored by Abbott Diabetes Care.

NCT05962710 is a clinical trial that was terminated before completion, run by Abbott Diabetes Care. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05962710 was terminated before completion, sponsored by Abbott Diabetes Care.

TERMINATED
Registry status
7 participants
Enrollment target

Study Summary

The purpose of this study is to characterize the FreeStyle Libre 3 Continuous Glucose Monitoring System performance with respect to YSI reference venous plasma sample measurements.

Primary Outcome

System Performance will be characterized with respect to YSI reference venous plasma measurements

Interventions

  • DEVICE FreeStyle Libre 3

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2023-01-27
Est. Completion 2023-01-31
Abbott Diabetes Care

26 total trials

Why NCT05962710 stopped before completion

NCT05962710 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which FreeStyle Libre 3 is the first listed.

NCT05962710 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05962710 about?

NCT05962710 is a clinical study titled "FreeStyle Libre 3 Continuous Glucose Monitoring System". The purpose of this study is to characterize the FreeStyle Libre 3 Continuous Glucose Monitoring System performance with respect to YSI reference venous plasma sample measurements.

What is the current status of trial NCT05962710?

This trial is currently terminated. The enrollment target is 7 participants. The study started on 2023-01-27. Estimated completion is 2023-01-31.

What interventions are being tested in trial NCT05962710?

The interventions under investigation include: FreeStyle Libre 3 (DEVICE).

Who is sponsoring clinical trial NCT05962710?

This trial is sponsored by Abbott Diabetes Care, which has 26 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05962710, the US trial registry maintained by the National Library of Medicine. NCT05962710 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.